PDE5 Inhibitors and Alzheimer’s Risk: What the Research Shows

PDE5 inhibitors are a class of medications that block the enzyme phosphodiesterase type 5, which regulates blood flow by allowing blood vessels to relax and widen. Originally developed for erectile dysfunction and pulmonary arterial hypertension, these medications are now being studied for a broader question: whether the vascular and cellular mechanisms behind them might also have implications for brain health and cognitive aging.

Much of the interest comes down to how these medications affect blood vessels and circulation, including blood flow to the brain. But researchers are also investigating other mechanisms that could influence cognitive health, and large observational studies have found some noteworthy associations.

That doesn’t mean PDE5 inhibitors have been proven to protect the brain or prevent cognitive decline. But the findings have raised questions worth investigating.

Key takeaways:

• PDE5 inhibitors affect blood flow and signaling pathways in the brain, which has sparked interest in their potential role in cognitive health
• Some large studies have linked PDE5 inhibitor use with a lower incidence of Alzheimer’s disease, including reductions as high as 44%
• The evidence is mixed. The NIH DREAM study and genetic research have not found the same protective association
• Most of the available human data comes from men, leaving important research gaps for women and other populations
• Researchers are still studying whether daily Tadalafil could have longer-term effects on brain health, but cognitive benefits have not been proven
• Tadalafil is not FDA-approved for cognitive health, Alzheimer’s disease, or longevity

What Are PDE5 Inhibitors and How Do They Work?

PDE5 inhibitors, such as Tadalafil, block an enzyme called phosphodiesterase type 5 (PDE5). This enzyme normally breaks down cGMP, a signaling molecule that helps smooth muscle relax and blood vessels widen. By slowing that breakdown, PDE5 inhibitors allow cGMP signaling to last longer, supporting increased blood flow. It’s the mechanism behind their use for erectile dysfunction and one reason researchers are interested in Tadalafil for longevity.

But cGMP does more than regulate blood vessel function. PDE5 is also found in neurons and glial cells in areas of the brain involved in learning and memory, including the hippocampus and cortex.

Within the brain, cGMP is involved in synaptic plasticity, the process that allows connections between brain cells to strengthen, weaken, and adapt over time. These changes are essential for learning and forming long-term memories.

This overlap has caught researchers’ attention. PDE5 inhibitors can influence circulation, while the cGMP pathway they act on also plays a role in how brain cells communicate and adapt. And because cGMP signaling can change with age, researchers are investigating whether PDE5 inhibition could have implications for cognitive health.

The mechanism gives us a reason to investigate. The more important question is whether those effects translate into measurable benefits in people.

What Do Observational Cohort Studies Show About PDE5 Inhibitors and Alzheimer’s?

Two studies put PDE5 inhibitors and brain health on researchers’ radar in a serious way.

A 2024 study followed 269,725 men with erectile dysfunction. Men prescribed PDE5 inhibitors had an 18% lower relative risk of developing Alzheimer’s disease compared with non-users. Among men who received 21-50 prescriptions, the association was even larger: a 44% lower relative risk.

Then came an even bigger analysis. A 2025 meta-analysis reviewed seven studies covering more than 4.8 million people. Across different comparison groups, PDE5 inhibitor use was associated with a lower incidence of Alzheimer’s disease, with pooled hazard ratios ranging from 0.41 to 0.47.

Those are attention-grabbing numbers. But there’s a key word in both findings: associated.

Neither study proves that PDE5 inhibitors caused the lower Alzheimer’s risk. People who regularly use these medications may differ from non-users in their health, healthcare habits, underlying conditions, and other ways that are difficult to fully account for. That leaves us with an intriguing signal, but not yet proof that PDE5 inhibitors protect the brain.

Why Do Studies on PDE5 Inhibitors Show Conflicting Results?

Study	Design	Population	Key Finding	Methodological Strength
Neurology 2024 cohort	Observational cohort	269,725 men with ED	44% relative risk reduction (HR 0.56) in highest-exposure group (20+ prescriptions)	Large sample; cannot control for healthy-user bias or reverse causality
npj Dementia 2025 meta-analysis	Meta-analysis (7 studies)	4.8 million+ individuals	HR 0.41-0.47 for Alzheimer’s incidence; evidence rated very low quality with very high heterogeneity	Enormous pooled sample; very high heterogeneity limits conclusions
NIH DREAM study	Active-comparator cohort	Pulmonary arterial hypertension patients (Medicare)	No reduction in Alzheimer’s or related dementia risk across 4 statistical approaches	Partially controls for healthy-user bias via active comparator design
Aging Cell 2025 MR study	Mendelian randomization	Genetic data from 4 GWAS	No causal association between PDE5 inhibition and Alzheimer’s risk	Largely immune to confounding and reverse causality; estimates lifelong genetic effect
PASTIS trial	Double-blind RCT crossover	55 participants with cerebral small vessel disease	Statistically inconclusive +9.8% cerebral blood flow increase (p = 0.0960); no cognitive benefit detected	Controlled design; single-dose only, cannot assess long-term neuroprotection

The meta-analysis still comes with notable limitations. The authors rated the overall certainty of evidence as moderate, but they also found considerable heterogeneity across studies. Differences in patient populations, reasons for taking PDE5 inhibitors, comparator groups, dosing, and follow-up make the pooled results harder to interpret.

Then there’s the problem of confounding. One major concern is healthy-user bias: people who regularly receive PDE5 inhibitor prescriptions may differ from non-users in ways that already affect Alzheimer’s risk, including their overall health, healthcare access, and underlying conditions. The meta-analysis itself notes that healthier or wealthier individuals may be more likely to access these medications, which could make the association look stronger than it really is.

Reverse causality may also play a role. Cognitive decline can begin years before an Alzheimer’s diagnosis, potentially changing sexual activity, healthcare behavior, and medication use before doctors formally diagnose the disease. In other words, some people may stop using PDE5 inhibitors because early disease is already developing, and not because PDE5 inhibitors prevent the disease.

Exposure is another challenge. Most observational studies rely on prescription records, but a filled prescription doesn’t tell us exactly how often someone took the medication or for how long. Twenty prescriptions over two years may represent very different exposure than 20 prescriptions spread across a decade. The meta-analysis calls out this lack of detailed compliance and dosing information as a limitation.

What Do the NIH DREAM Study and Genetic Research Show About PDE5 Inhibitors and Alzheimer’s?

So far, the observational data sounds promising. But when researchers tested the same question using methods designed to reduce some of the biases we just covered, the picture changed.

The NIH DREAM study used Medicare data from people treated for pulmonary arterial hypertension. Instead of comparing PDE5 inhibitor users with people who weren’t taking them, researchers compared patients taking Sildenafil or Tadalafil with patients taking a different class of medications for the same condition. That gave researchers more comparable groups and helped reduce some of the healthy-user bias seen in ED studies. Across four different analyses, they found no meaningful reduction in Alzheimer’s disease or related dementia risk.

A 2025 Mendelian randomization study approached the question from a completely different angle. Instead of tracking prescriptions, researchers used naturally occurring genetic differences related to PDE5 inhibition to look for a connection with Alzheimer’s risk.

Think of it as a kind of natural experiment. Because people inherit these genetic differences at conception, lifestyle, health behaviors, or early disease changes that can complicate observational studies have less influence on them.

Across four large genetic datasets, researchers found no evidence that PDE5 inhibition causally reduced Alzheimer’s risk.

Neither study closes the case. DREAM looked at people with pulmonary arterial hypertension, so its findings may not translate directly to otherwise healthy adults. Mendelian randomization also estimates the effects of lifelong genetically predicted differences in a biological target, which is not the same as taking a specific PDE5 inhibitor at a specific dose later in life.

Still, these studies add a meaningful reality check. The observational signal is interesting, but when researchers used different methods to test whether PDE5 inhibition itself might be driving the association, the protective effect did not hold up.

How Could PDE5 Inhibitors Affect Brain Health?

Researchers are looking into two main possibilities: PDE5 inhibitors could affect the blood vessels that supply the brain, the neurons within it, or potentially both.

The Vascular Pathway: Supporting Blood Flow to the Brain

The vascular hypothesis starts with blood flow. PDE5 inhibition widens blood vessels, which could influence cerebral blood flow and vascular function. That matters because damage to the brain’s small blood vessels can contribute to cognitive impairment, and cerebrovascular disease often overlaps with Alzheimer’s disease.

The Neuronal Pathway: Supporting Brain Cell Signaling

The neuronal hypothesis looks inside the brain cells themselves. As we covered earlier, increasing cGMP can activate signaling involved in synaptic plasticity and memory formation. Animal studies have also found evidence that Tadalafil can reach the brain and have reported changes in amyloid burden and cognitive performance in some Alzheimer’s models.

The Catch: Animal Research Doesn’t Always Translate to Humans

Many Alzheimer’s mouse models are genetically engineered to develop specific features of the disease. That doesn’t perfectly recreate the more complex, late-onset Alzheimer’s disease seen in most people. Evidence that Tadalafil reaches the brain in animal models also doesn’t tell us exactly what happens at standard clinical doses in humans.

Both pathways give researchers a biological reason to keep looking. But neither has been confirmed as the mechanism by which PDE5 inhibitors improve cognitive outcomes in humans.

What Did the PASTIS Trial Find About Tadalafil and Brain Blood Flow?

The PASTIS trial gave researchers an early opportunity to test Tadalafil and brain blood flow directly in humans.

In this double-blind, placebo-controlled crossover trial, 55 people with cerebral small vessel disease received a single 20 mg dose of Tadalafil and a placebo on separate visits. Researchers then measured changes in cerebral blood flow.

Did Tadalafil Increase Blood Flow to the Brain?

Tadalafil increased cerebral blood flow across several subcortical brain regions, but the changes were below the threshold for statistical reliability. The largest difference appeared in areas with white matter hyperintensities, where blood flow increased by 9.8% compared with placebo. However, that result did not reach statistical reliability (P=.096).

Researchers also tested attention, processing speed, working memory, and other cognitive measures. A single dose of Tadalafil produced no overall measurable improvement in cognitive performance. However, there is still an upside to these findings.

What Can We Actually Learn From PASTIS?

PASTIS tested one 20 mg dose. That tells us about the brain’s short-term response to Tadalafil, but not what could happen with regular use over months or years.

If PDE5 inhibition has any meaningful effect on cognitive health, a single dose may simply be too short a window to detect it. The researchers themselves noted that different dosing regimens may be needed to identify an effect.

So PASTIS gave researchers a notable early signal, but not proof. It showed that Tadalafil could be studied safely in this population and produced numerical changes in cerebral blood flow, but it did not show a statistically meaningful improvement in cerebral blood flow or cognition after a single dose.

Could Daily Low-Dose Tadalafil Have Different Effects Over Time?

PASTIS leaves us with a core question: could daily Tadalafil use look different from a single dose?

Researchers have started testing that idea. The ETLAS-2 trial studied 20 mg of Tadalafil daily for three months in people with cerebral small vessel disease. The trial did not find an overall improvement in cognition. However, a later MRI analysis found increased whole-brain cerebral blood flow after three months of treatment.

That still doesn’t tell us what happens with lower doses taken consistently over years. In fact, the ETLAS-2 researchers called for larger, longer studies and suggested that future trials test lower Tadalafil doses.

That distinction is especially relevant to longevity. Daily Tadalafil protocols typically use much lower doses than the 20 mg studied in PASTIS and ETLAS-2. The goal is steady PDE5 inhibition over time instead of the higher exposure of a single dose.

Whether that translates into better cognitive outcomes remains unknown. But it’s a worthwhile question for future research, particularly as researchers continue studying the connection between vascular health, brain blood flow, and cognitive aging.

Interested in Tadalafil?

AgelessRx offers several Tadalafil options depending on your goals, including daily Tadalafil tablets, our new first-ever Tadalafil Longevity Gummy, and as-needed Tadalafil.

For those interested in a daily longevity protocol, our tablet and gummy options provide low-dose Tadalafil designed for consistent use under clinician guidance.

While research into Tadalafil and brain health continues to evolve, Tadalafil is not FDA-approved for cognitive health, Alzheimer’s disease, or longevity.

Frequently Asked Questions

Note: The above statements have not been reviewed by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.